Besides, immunohistochemistry (IHC) staining in the discovery cohort corroborated the higher NANS expression in tumor tissues of subgroup 2 compared to subgroup 1 and 3, which has been further validated by proteomic data of the validation cohort 1 (Fig. 3G-H). This evidence concerns the gene NANS and neoplasm.